Shares of Regulus Therapeutics Inc. were up more than 10% in extended trading on Tuesday after the company announced that its preclinical drug candidate RG-125 (AZD4076), a microRNA therapeutic for the treatment of NASH in patients with type 2 diabetes/pre-diabetes, has been selected for clinical development by AstraZeneca plc.